THE IL-17 FAMILY OF CYTOKINES IMMUNOLOGICAL AND IMMUNOPATHOLOGICAL ASPECTS, PSORIASIS TREATMENT WITH IL-17 INHIBITOR – SECUKINUMAB
DOI:
https://doi.org/10.52340/jecm.2025.01.27Keywords:
IL-17 family, monoclonal antibodies, psoriasis, secukinumabAbstract
IL-17 refers to a family of proteins that play critical role against bacterial and fungal infections and in the pathogenesis of autoimmune diseases. Skin diseases in which interleukin-17 is involved or is thought to be involved is psoriasis. Psoriasis is a chronic inflammatory skin condition characterized by epidermal hyperplasia. The role of new therapeutic agents – biological agents, mAbs or monoclonal antibodies - designed to manage psoriasis has been growing and becoming increasingly important in recent years. Secukinumab is a new biological agent targeting interleukin 17. This is a fully human monoclonal antibody IgG1/kappa isotype, which has been registered on the Georgian market since 2021 and is effectively used for the treatment of both psoriasis and psoriatic arthritis. The drug has a commendable safety profile and long-lasting clinical effect.
Downloads
References
Chunfang Gu, Ling Wu, Xiaoxia Li. IL-17 family: cytokines, receptors and signaling Cytokine. Author manuscript; available in PMC: 2014 Nov 1. Published in final edited form as: Cytokine. 2013 Sep 3;64(2):10.1016/j.cyto.2013.07.022. doi: 10.1016/j.cyto.2013.07.022
Ye P, Garvey PB, Zhang P, et al. Interleukin-17 and lung host defense against Klebsiella pneumoniae infection. Am J Respir Cell Mol Biol. 2001;25(3):335–40. doi:10.1165/ajrcmb.25.3.4424.
Dubin PJ, Martz A, Eisenstatt JR, et al. Interleukin-23-mediated inflammation in Pseudomonas aeruginosa pulmonary infection. Infect Immun. 2012;80(1):398–409. doi:10.1128/IAI.05821-11.
Shen F, Gaffen SL. Structure-function relationships in the IL-17 receptor: implications for signal transduction and therapy. Cytokine. 2008;41(2):92–104. doi:10.1016/j.cyto.2007.11.013.
Reynolds JM, Martinez GJ, Nallaparaju KC, Chang SH, Wang YH, Dong C. Cutting edge: regulation of intestinal inflammation and barrier function by IL-17C. J Immunol. 2012;189(9):4226–30. doi:10.4049/jimmunol.1103014.
Ishigame H, Kakuta S, Nagai T, et al. Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity. 2009;30(1):108–19.
Owyang AM, Zaph C, Wilson EH, et al. Interleukin 25 regulates type 2 cytokine-dependent immunity and limits chronic inflammation in the gastrointestinal tract. J Exp Med. 2006;203(4):843–9. doi:10.1084/jem.20051496.
Monin L, Gaffen SL. Interleukin 17 family cytokines: signaling mechanisms, biological activities, and therapeutic implications. Cold Spring Harb Perspect Biol. 2018;10(4):a028522. doi:10.1101/cshperspect.a028522.
Flores R, de la Fuente R, Bozán F, Vergara K, Valenzuela F. Actualización en terapia biológica para psoriasis y artritis psoriática (parte I): moléculas pequeãas, inhibidores de JAK y agentes biológicos (inhibidores IL-17) Lat Am J Clin Sci Med Technol. 2020;2:113–25. doi: 10.1016/j.autrev.2016.09.015.
Özyurt K, Ertaş R, Atasoy M. Biologics for psoriasis: What is new? Dermatol Ther. 2019;32(3):e12916.
Elman SA, Weinblatt M, Merola JF. Targeted therapies for psoriatic arthritis: an update for the dermatologist. Semin Cutan Med Surg. 2018 Sep;37(3):173-181.
Yiu ZZ, Warren RB. Ustekinumab for the treatment of psoriasis: an evidence update. Semin Cutan Med Surg. 2018 Sep;37(3):143-147.
Yang EJ, Beck KM, Sanchez IM, Koo J, Liao W. The impact of genital psoriasis on quality of life: a systematic review. Psoriasis (Auckl). 2018;8:41-47.
Gamret AC, Price A, Fertig RM, Lev-Tov H, Nichols AJ. Complementary and Alternative Medicine Therapies for Psoriasis: A Systematic Review. JAMA Dermatol. 2018 Nov 01;154(11):1330-1337.
Luchetti MM, Benfaremo D, Campanati A, Molinelli E, et al. Clinical outcomes and feasibility of the multidisciplinary management of patients with psoriatic arthritis: two-year clinical experience of a dermo-rheumatologic clinic. Clin Rheumatol. 2018 Oct;37(10):2741-2749.
Papp KA et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2013;168(2):412-21.
S Garcês, J Demengeot. The Immunogenicity of Biologic Therapies. Curr Probl Dermatol, 53 (2018), pp. 37-48 http://dx.doi.org/10.1159/000478077 | Medline https://doi.org/10.1159/issn.1421-5721
Garcês S, Demengeot J. The Immunogenicity of Biologic Therapies. Curr Probl Dermatol. 2018;53:37–48.
Koenders MI, van den Berg WB. Secukinumab for rheumatology: development and its potential place in therapy. Drug Des Devel Ther. 2016;10:2069-80.
Frieder J, Kivelevitch D, Menter A. Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis. Ther Adv Chronic Dis. 2018 Jan;9(1):5-21.
Stubenrauch, K., Wessels, U., Regula, J.T., Kettenberger, H., Schleypen, J. & Kohnert, U. Impact of molecular processing in the hinge region of therapeutic IgG4 antibodies on disposition profiles in cynomolgus monkeys. Drug Metab. Dispos. 38, 84–91 (2010).
Karle A et al. Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity. MAbs. 2016;8(3):536–50.
Reich K, Blauvelt A. et al. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years. J Eur Acad Dermatol Venereol. 2019;33(9):1733–41.
Koenders MI, van den Berg WB. Secukinumab for rheumatology: development and its potential place in therapy. Drug Des Devel Ther. 2016;10:2069-80.
Smith CH, Jabbar-Lopez ZK, Yiu ZZ, Bale T, Burden AD, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol. 2017 Sep;177(3):628-636.
Downloads
Published
How to Cite
Issue
Section
